Literature DB >> 32253449

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Qiurong Ruan1,2, Kun Yang3, Wenxia Wang4, Lingyu Jiang5, Jianxin Song6.   

Abstract

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Entities:  

Year:  2020        PMID: 32253449      PMCID: PMC7131986          DOI: 10.1007/s00134-020-06028-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


Correction to: Intensive Care Med https://doi.org/10.1007/s00134-020-05991-x

The original version of this article unfortunately contained mistakes. There is an incorrect unit of IL-6 in Fig. 1 and Supplementary Table 1. It should be pg/mL rather than ng/mL. The corrected Fig. 1 and Supplementary Table 1 can be found below. The authors apologize for the mistakes.
Fig. 1

a Age distribution of patients with confirmed COVID-19; b key laboratory parameters for the outcomes of patients with confirmed COVID-19; c interval from onset of symptom to death of patients with confirmed COVID-19; d summary of the cause of death of 68 died patients with confirmed COVID-19

a Age distribution of patients with confirmed COVID-19; b key laboratory parameters for the outcomes of patients with confirmed COVID-19; c interval from onset of symptom to death of patients with confirmed COVID-19; d summary of the cause of death of 68 died patients with confirmed COVID-19 Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19 Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values. ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 21 kb)

Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19

Normal Range Died (N = 68) Discharged (N = 82) p-value
Demographics
Age, years67 (15-81)50 (44-81)<0.001
Sex
Male49 (72%)53 (65%)
Female19 (28%)29 (35%)
Comorbidities43 (63%)34 (41%)0.01
Hypertension29 (43%)23 (28%)0.07
Cardiovascular disease13 (19%)0<0.001
Diabetes12 (18%)13 (16%)0.88
Cerebrovascular disease7 (10%)5 (6%)0.49
Chronic obstructive pulmonary disease2 (3%)1 (1%)0.59
Chronic kidney disease2 (3%)00.20
Malignancy2 (3%)1 (1%)0.59
Chronic liver disease1 (1%)3 (4%)0.63
Connective tissue disease1 (1%)00.45
Signs and Symptoms
Fever59 (87%)68 (83%)0.67
Cough51 (75%)59 (72%)0.81
Sputum production29 (43%)25 (30%)0.17
Fatigue15 (22%)22 (27%)0.63
Myalgia9 (13%)10 (12%)1
Haemoptysis3 (4%)00.09
Dyspnea59 (87%)51 (62%)0.001
Respiratory failure58 (85%)13 (16%)<0.001
ARDS55 (81%)7 (9%)<0.001
Acute kidney injury21 (31%)2 (2%)<0.001
Infection11 (16%)1 (1%)0.002
Treatments
ICU admission30 (44%)11 (13%)<0.001
High flow nasal cannula31 (46%)10 (12%)<0.001
Non-invasive mechanical ventilation46 (68%)5 (6%)<0.001
Invasive mechanical ventilation25 (37%)0<0.001
ECMO7 (10%)00.003
CRRT5 (7%)00.02
Prone position mechanical ventilation3 (4%)00.09
Antiviral treatment33 (49%)55 (67%)0.05
Antibiotic treatment63 (93%)80 (98%)0.66
Antifungal treatment12 (18%)5 (6%)0.04
Glucocorticoid treatment31 (46%)22 (27%)0.02
Time from onset of symptom to start of Glucocorticoid treatment, days11.7 (6.9)11.4 (4.4)0.89
Time from hospital admission to start of Glucocorticoid treatment, days1.5 (1.2)3.2 (2.7)0.01
Glucocorticoid treatment duration, days7.2 (6.7)7.0 (5.0)0.92
Supportive therapy45 (66%)18 (22%)<0.001
Length of stay, days7.4 (5.5)12.3 (4.4)<0.001
Laboratory Findings
Time from onset of symptom to test, days11.6 (6.8)9.8 (4.3)0.07
White blood cell count, × 109/L3.50-9.5010.62 (4.76)6.76 (3.49)<0.001
Lymphocyte count, × 109/L1.10-3.200.60 (0.32)1.42 (2.14)<0.001
Haemoglobin, g/L130.0-175.0127.0 (16.7)127.6 (16.3)0.82
Platelet count, × 109/L125.0-350.0173.6 (67.7)222.1 (78.0)<0.001
Albumin, g/L35.0-52.028.8 (3.8)32.7 (3.8)<0.001
Alanine aminotransferase, U/L9.0-50.0170.8 (991.6)48.68 (83.1)0.35
Aspartate aminotransferase, U/L15.0-40.0288.9 (1875.5)40.7 (57.8)0.31
Total bilirubin, μmol/L0.0-26.018.1 (10.7)12.8 (6.8)0.001
Blood urea nitrogen, mmol/L3.1-8.08.65 (4.5)5.11 (2.1)<0.001
Creatinine, umol/L59.0-104.091.2 (56.2)72.1 (22.2)0.02
Creatine kinase, U/L50.0-310.0319.4 (838.5)231.7 (862.3)0.56
Lactate dehydrogenase, U/L120.0-250.0905.8 (2619.1)297.9 (110.4)0.08
Cardiac troponin, pg/mL2.0-28.030.3 (151.0)3.5 (6.2)<0.001
Myoglobin, ng/mL0.0-146.9258.9 (307.6)77.7 (136.1)<0.001
C-reactive protein, mg/L0.0-5.0126.6 (106.3)34.1 (54.5)<0.001
Interleukin-6, pg/mL0.0-7.011.4 (8.5)6.8 (3.61)<0.001
Serum ferritin, ng/mL21.8-274.71297.6 (1030.9)614.0 (752.2)<0.001

Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values.

ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy.

  133 in total

1.  Myalgia may not be associated with severity of coronavirus disease 2019 (COVID-19).

Authors:  Giuseppe Lippi; Johnny Wong; Brandon Michael Henry
Journal:  World J Emerg Med       Date:  2020

2.  Clinical Course of COVID-19 in Identical Twins.

Authors:  Mishita Goel; Victoria Gonzalez; Reina Badran; Vesna Tegeltija
Journal:  J Med Cases       Date:  2020-08-28

3.  Renal complications in COVID-19: a systematic review and meta-analysis.

Authors:  Setor K Kunutsor; Jari A Laukkanen
Journal:  Ann Med       Date:  2020-07-10       Impact factor: 4.709

4.  Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists.

Authors:  Maximilian F Konig; Mike Powell; Verena Staedtke; Ren-Yuan Bai; David L Thomas; Nicole Fischer; Sakibul Huq; Adham M Khalafallah; Allison Koenecke; Ruoxuan Xiong; Brett Mensh; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Joshua T Vogelstein; Susan Athey; Shibin Zhou; Chetan Bettegowda
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

5.  Principles for clinical care of patients with COVID-19 on medical units.

Authors:  David W Frost; Rupal Shah; Lindsay Melvin; Miguel Galán de Juana; Thomas E MacMillan; Tarek Abdelhalim; Alison Lai; Shail Rawal; Rodrigo B Cavalcanti
Journal:  CMAJ       Date:  2020-06-03       Impact factor: 8.262

6.  Multisystem Imaging Manifestations of COVID-19, Part 2: From Cardiac Complications to Pediatric Manifestations.

Authors:  Margarita V Revzin; Sarah Raza; Neil C Srivastava; Robin Warshawsky; Catherine D'Agostino; Ajay Malhotra; Anna S Bader; Ritesh D Patel; Kan Chen; Christopher Kyriakakos; John S Pellerito
Journal:  Radiographics       Date:  2020 Nov-Dec       Impact factor: 5.333

7.  Viral infection-induced thrombosis, novel coronavirus.

Authors:  Lemuel Pran; Shanta Baijoo; Hani Slim
Journal:  J Vasc Surg       Date:  2020-05-11       Impact factor: 4.268

8.  Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.

Authors:  Pavel Šmak; Selvaraj Chandrabose; Igor Tvaroška; Jaroslav Koča
Journal:  Glycobiology       Date:  2021-04-01       Impact factor: 4.313

Review 9.  Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.

Authors:  Shivraj Padiyar; Debashish Danda
Journal:  Eur J Rheumatol       Date:  2020-10-08

10.  Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.

Authors:  Wen-Hao Niu; Feng Wu; Wen-Yue Cao; Zong-Gui Wu; Yu-Chieh Chao; Chun Liang
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.